Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2015. The report serves as a Director Declaration pursuant to Listing Rule 9.6.14, notifying the market of a change in the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification and does not contain financial performance data.
Material Changes
The material change disclosed is the appointment of Dr. Stephanie Burns, a Non-Executive Director of GlaxoSmithKline plc, to the Board of HP Inc. effective November 1, 2015.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Dr. Stephanie Burns has been appointed as a Director to the Board of HP Inc.
- The appointment took effect on November 1, 2015.
- The filing was signed by Victoria Whyte, Company Secretary, on November 2, 2015.